Domainex

Who we are :

Greenpharma is a CRO SME of 12 people, specialised in natural compound studies for cosmetic, food and pharmaceutical industries.
Built around an innovative technological platform, Greenpharma succeeded to gather expertise in wide and complementary fields such as chemoinformatic, pharmacognosy, medicinal & analytical chemistry, pilot scale extraction and formulation. This has led to a unique know-how in natural compound & extract selection, extract purification, metabolite measurement, homology modelling, virtual screening (e.g. Selnergy™), lead optimisation, ADMET prediction and database building. Greenpharma approach has led to several patents on bioactive (natural or synthetic) molecules and extracts.

What we do:

Greenpharma provides natural or synthetic compounds for high throughput screening. It utilises in silico tools to select the most relevant molecules (we have access to a database of 20 millions commercial compounds).

We provide the industries of pharmacy, cosmetics and agro-food with innovative bio-active molecules through R&D projects.
Our services include:

• Phytochemistry: development of methods for extraction, purification (until pilot scale) and characterisation of metabolites in complex matrices, activity-guided fractionations;

• Molecular modelling: ligand and structure-based virtual screening, QSAR, in silico activity identification (eg drug repositioning, identification of activities for natural compounds...) with our proprietary tool Selnergy;

• Knowledge management: database design and building.

• Medicinal chemistry: synthesis on demand, lead optimisation, natural compound mimics (eg. Pyrazolotriazine...), library design...

• Pilot extraction: development of pre-industrial method to produce cosmetic/food ingredients

• Formulation: development of formulation for cosmetic and dermocosmetic products

Aurora Fine Chemicals is a privately held company that was founded in 1990. As a chemicals R&D supplier we offer chemicals for R&D, drug discovery service, compound libraries and custom synthesis. We have one of the largest collections of 18.1 mln. chemicals available in stock and our docking software delivers hits/leads of very high quality in short time.

Our staff consists of highly qualified individuals with Bsc, Msc and Ph.D. degrees in chemistry, as well as excellent laboratory technicians. In our Molecular Modeling Group are professionals specializing in computational drug design. They possess many years experience of working in the chemistry of heterocycles, carbohydrates, nucleosides and elemental organic compounds. Aurora has significant expertise in synthesis of all types R&D chemicals for drug discovery like small molecules, natural products and peptides. Parallel synthesis with well-designed, targeted and fragment-based libraries is the favored approach to lead optimization. Rational design is the strategy for projects driven by structural biology, such as enzyme inhibitors or protein interactions.

We own a large library of 18.1 million stocked compounds for R&D. Our substances are used in many research labs all over the world. We offer structures for biochemical and chemical research. Our products are applied in pharmaceutical development, diagnosis, and in chemical production.

Several laboratories for synthesis with modern equipment such as reactors, autoclaves, thermostats and hydrogenation equipment are available.

Intermediates and final products are analyzed by GC, HPLC, IR, NMR, MS, elemental analysis, atom-absorption analysis and crystallographical methods.

The main advantage of Aurora's own software is the quality of the underlying physical models. Aurora's software derives molecular properties from first principles based on direct models using advanced quantum mechanical analysis of molecular interactions and thermodynamics.

Founded in 2013, BioAscent is a leading provider of integrated drug discovery services. Our expert scientists provide medicinal chemistry, in vitro biosciences and compound management services from our base in the former Organon / Merck Sharpe and Dohme (MSD) R&D site in Newhouse, Scotland, and via Compound Cloud we offer access to an IP-free compound library in assay ready format.

Our drug discovery services include de novo assay development, target analysis and bespoke screening strategies, compound screening, medicinal and synthetic chemistry, computational chemistry and data management (>100 biochemical and biophysical assays established for drug discovery projects, >50 hit validation/characterisation projects, and >25 hit-to-lead campaigns since 2013). Our team of expert scientists has experience of successfully working from assay development through to preclinical and clinical candidates across all biological target classes and major therapeutic indications.

We currently hold and manage over 1 million compounds for our customers in our €20 million facility, storing and managing customer libraries ranging in size from a few thousand to a few hundred thousand compounds in both liquid and solid formats. We constantly receive and aggregate new compounds from our customers and their chemistry CRO partners, and ship in the assay-ready format of choice to their screening laboratories

Via our Compound Cloud service, we provide rapid access to an IP-free library of ~125,000 lead like compounds in screening-ready format. Our expertise in cherry picking, reformatting, shipping and data management have allowed us to deliver over 80,000 screening plates globally to our customers and their partner testing laboratories since 2013.

We are located in modern purpose-built laboratories on a single site, the former Organon / Merck Sharpe and Dohme (MSD) research & development facility, based within the BioCity Scotland campus at Newhouse, Scotland, UK.

Eyen is the expert in molecular imaging and nano-scale structural data analysis. Our expertise lies in advanced computational analysis of proteins, biologics and nanoparticles for pharmaceutical research & development.

Celine3D, our unique, market's most comprehensive "gene-to-structure"​ 3D cryo-electron microscopy service provides outsourcing for your protein, biologics and nanoparticle structural characterization needs.

We routinely provide high-resolution cryoEM structure determination as a service that includes protein sample evaluation and 3D screening using negative stain EM, cryo grid preparation and optimization, high-end imaging, map reconstruction and model building.

Jointly with Crelux GmbH, we also provide within Celine3D an option for extensive protein production services specifically optimized to meet the needs of cryoEM structure determination, making the whole process from gene to structure a streamlined, effective and worry-free experience.

AI based drug design and large-scale virtual screenings to identify suitable therapeutics from small molecules to biopharmaceuticals.

Innophore uses a new and unique way to identify enzymes and drugs for existing or up-coming industrial biocatalytic processes and pharmaceutical application. The CatalophoreTM platform enables companies to make ground breaking discoveries with an exclusive database of 3D enzyme cavities.
The CatalophoreTM platform is a digital search engine provided to industrial partners in the areas Pharmaceuticals, Fine and bulk chemicals, Biotherapeutics, Food & Beverage, Cosmetic, Industry or Molecular Diagnostics. Companies benefit from the application within finding altered protein properties such as thermo- and solvent stability, substrate spectrum, selectivity and specificity. Based on spacial features of active sites of enzymes, new in-silico methods are used to identify enzyme candidates using the CatalophoreTM platform, a combination of a comprehensive ready-to-use structural database of biomolecules and unique search algorithms and tailored patterns.
Compared to classic digital and manual laboratory searches, the CatalophoreTM platform offers a unique, target-oriented search for alternative enzymes leading to a reduced time-to market for products. The approach differs vastly from other offerings as it is independent of the overall structure, protein fold and amino acid sequence. This platform can drastically improve the cost and quality of pharmaceuticals, food, chemical compounds or the way new therapies are developed.